首页> 外文期刊>Frontiers in Laboratory Medicine >Prognostic value of Bmi-1 oncoprotein expression in non-small cell lung cancer
【24h】

Prognostic value of Bmi-1 oncoprotein expression in non-small cell lung cancer

机译:Bmi-1癌蛋白表达在非小细胞肺癌中的预后价值

获取原文
       

摘要

Background: In our prior study, Bmi-1 was elevated in non-small cell lung cancer (NSCLC) and took an important role in the early stage of progression. However, the clinical significance of Bmi-1 in NSCLC was uncertain. The aim of this study was to illuminate the relationship between Bmi-1, clinical variables and the prognosis of patients with NSCLC. Methods: Real-time PCR was used to examine the expression of Bmi-1 mRNA in 23 paired NSCLC and the adjacent normal tissues. The expression of Bmi-1 protein in 128 specimens of NSCLC was determined by immunohistochemistry assay. Statistical analyses were performed to evaluate the association between the expression of Bmi-1, clinicopathologic features and prognosis. Results: Up-regulated expression of Bmi-1 mRNA was observed in 91.3% of NSCLC ( P ??0.0001). The level of Bmi-1 was positively correlated with T stage ( P ?=?0.019), and the 5-year overall survival of patients with higher Bmi-1 level was lower than that of patients with lower Bmi-1 level without statistical significance ( P ?=?0.189). Histological classification and smoking status were not related to prognosis ( P ?=?0.166, 0.615). For patients with adenocarcinoma, lower level of Bmi-1 was related to good prognosis ( P ?=?0.033), and in multivariate analysis, metastasis, T stage and lymph node involvement were independent prognostic factors ( P ?=?0.001, 0.044, 0.013). Conclusions: Expression of Bmi-1 mRNA was higher in NSCLC than in the adjacent normal tissues. The detection of Bmi-1 protein expression is potentially useful in prognostic evaluation of lung adenocarcinoma.
机译:背景:在我们先前的研究中,Bmi-1在非小细胞肺癌(NSCLC)中升高,并且在进展的早期阶段起着重要作用。但是,Bmi-1在NSCLC中的临床意义尚不确定。这项研究的目的是阐明Bmi-1,临床变量与非小细胞肺癌患者预后之间的关系。方法:采用实时荧光定量PCR检测23对配对的NSCLC及附近正常组织中Bmi-1 mRNA的表达。免疫组化法检测128例NSCLC标本中Bmi-1蛋白的表达。进行统计分析以评估Bmi-1的表达,临床病理特征和预后之间的关系。结果:在91.3%的NSCLC中观察到Bmi-1 mRNA的表达上调(P≤<0.0001)。 Bmi-1的水平与T期呈正相关(P?=?0.019),Bmi-1较高的患者的5年总生存率低于Bmi-1较低的患者,但无统计学意义。 (P≤0.189)。组织学分类和吸烟状况与预后无关(P = 0.166,0.615)。对于腺癌患者,较低的Bmi-1水平与良好的预后相关(P = 0.033),在多因素分析中,转移,T分期和淋巴结转移是独立的预后因素(P = 0.001、0.044, 0.013)。结论:NSCLC中Bmi-1 mRNA的表达高于邻近的正常组织。 Bmi-1蛋白表达的检测可能对肺腺癌的预后评估有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号